What is it about?
Perioperative intravenous NAC in patients undergoing right-lobe living donor OLT was safe as there was a decreased incidence of postoperative complications, and a decrease in the dose of loop diuretics, the need for dopamine dose, renal replacement therapy, the hospital duration and the ICU stay, but no eff ect on the number of ventilator days and mortality.
Featured Image
Why is it important?
In the present study, on admission and during 7 and 14 days, there was a signifi cant reduction in the incidence of patients classifi ed as risk, injury, and failure using the maximum RIFLE classifi cation, and in the serum lactate and the serum creatinine levels, with an increase in the UOP in the NAC group.
Perspectives
Perioperative intravenous NAC administration in patients undergoing living donor liver transplantation decreased incidence of postoperative acute kidney injury, severity of PRS and PGNF along with decreased length of ICU and hospital stay with no adverse events , But did not significantly reduce mechanical ventilator days and mortality but another large randomized trial needed to detect the effect of NAC infusion post liver transplant as regards donor liver profile post hepatectomy and recipient glypressin dose when indicated
Dr Hanaa Abd Allah El Gendy
Ain Shams University
Read the Original
This page is a summary of: Perioperative N-acetylcysteine for patients undergoing living donor orthotopic liver transplantation, Ain-Shams Journal of Anaesthesiology, January 2015, Medknow,
DOI: 10.4103/1687-7934.172668.
You can read the full text:
Contributors
The following have contributed to this page
